Use of Tamoxifen in Systemic Mastocytosis
Use of Tamoxifen in Systemic Mastocytosis
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic
 agent, to improve quality of life, biochemical parameters, and bone marrow involvement in
 systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells
 and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard
 "non-cytotoxic" medications regardless of the percentage bone marrow involvement by
 mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be
 for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine
 will be excluded until these medications have been stopped.
Not desired
Inclusion Criteria:

 -  Systemic Mastocytosis

 Exclusion Criteria:

 -  Current treatment with Imatinib mesylate, cladribine or interferon alpha.